Mark Litton
2021 - Athira Pharma
In 2021, Mark Litton earned a total compensation of $3M as President and Chief Executive Officer at Athira Pharma.
Compensation breakdown
| Non-Equity Incentive Plan | $256,200 |
|---|---|
| Option Awards | $1,328,006 |
| Salary | $450,000 |
| Stock Awards | $920,400 |
| Other | $83 |
| Total | $2,954,689 |
Litton received $1.3M in option awards, accounting for 45% of the total pay in 2021.
Litton also received $256.2K in non-equity incentive plan, $450K in salary, $920.4K in stock awards and $83 in other compensation.
Rankings
In 2021, Mark Litton's compensation ranked 4,487th out of 12,415 executives tracked by ExecPay. In other words, Litton earned more than 63.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,487 out of 12,415 | 64th |
Division Manufacturing | 1,849 out of 5,505 | 66th |
Major group Chemicals And Allied Products | 771 out of 2,375 | 68th |
Industry group Drugs | 686 out of 2,096 | 67th |
Industry Biological Products, Except Diagnostic Substances | 173 out of 449 | 62nd |
Source: SEC filing on April 5, 2023.
Litton's colleagues
We found two more compensation records of executives who worked with Mark Litton at Athira Pharma in 2021.